Report from the extraordinary general meeting of Biokraft International AB (publ)

Stockholm, 27 March 2024

Biokraft International AB (publ), reg.no 556528-4733, has today held an extraordinary general meeting, at which the following was resolved. The meeting was conducted with the possibility to participate through postal voting.

Resolutions to amend the Articles of Association

The extraordinary general meeting resolved, in accordance with the Board of Directors' proposal, to amend the company’s Articles of Association, whereby the limits of the share capital are changed to a minimum of SEK 87,000,000 and a maximum of SEK 348,000,000 and the number of shares to a minimum of SEK 43,500,000 and a maximum of SEK 174,000,000.

The Board of Directors’ proposal for a possible second amendment of the Articles of Association to enable issues larger than what can be accommodated within the Board of Director’s first proposal to amend the Articles of Association, did not reach the required majority and was therefore not adopted.

Issue authorisations

The Board of Directors’ proposal to authorise the Board of Directors to, on one or more occasions during the period until the next annual general meeting, resolve on a rights issue of shares with pre-emptive rights for the company's existing shareholders of a total amount of up to approximately SEK 650 million, after deduction of issue costs, to finance repurchase of its senior secured green bonds did not reach the required majority and was therefore not adopted.

This means that the intended rights issue announced by the company on 26 February 2024 will not be conducted.

The extraordinary general meeting resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, on one or more occasions during the period until the next annual general meeting, resolve to issue new shares with or without pre-emptive rights for the company's existing shareholders. Share issues both with and without pre-emptive rights for the company’s existing shareholders, by virtue of the authorisation, may amount to a total of up to approximately SEK 150 million to be used for investments in the company's ongoing operations as well as for further growth and expansion. The authorisation replaces the current existing issue authorization as resolved at the annual general meeting 2023.

The information was submitted, through the care of the contact person below, for publication on 27 March 2024, at 10:35 CET.

For more information, please contact:
Matti Vikkula, CEO Biokraft International AB 
Telephone +46-70 597 99 38
Email: matti.vikkula(at)biokraft.com

Biokraft is a Nordic greentech company that produces bioenergy and plant nutrition in a circular cycle by recycling organic waste and residual products in large-scale biorefineries. Biogas is CO2-neutral and lowers GHG emissions by over 100% when replacing fossil fuels. Biokraft will build, own and operate large-scale biogas plants with a focus on the Northern European market. Today there are facilities in Sweden, Norway and Korea. Biokraft has just over 120 employees and had total revenues of SEK 534 million in 2023. The company is listed on the Nasdaq First North Premier Growth Market. The Certified Adviser is Carnegie Investment Bank AB (publ). www.biokraft.com